Browsing Bergen Open Research Archive by Author "Mittelbronn, Michel"

Now showing items 1-3 of 3

    • Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas 

      Fack, Fred; Espedal, Heidi; Keunen, Olivier; Golebiewska, Anna; Obad, Nina; Harter, Patrick N.; Mittelbronn, Michel; Bähr, Oliver; Weyerbrock, Astrid; Stuhr, Linda Elin Birkhaug; Miletic, Hrvoje; Sakariassen, Per Øystein; Stieber, Daniel; Rygh, Cecilie Brekke; Lund-Johansen, Morten; Zheng, Liang; Gottlieb, Eyal; Niclou, Simone P.; Bjerkvig, Rolf (Peer reviewed; Journal article, 2015-01)
      Anti-angiogenic therapy in glioblastoma (GBM) has unfortunately not led to the anticipated improvement in patient prognosis. We here describe how human GBM adapts to bevacizumab treatment at the metabolic level. By performing ...

    • Patient-derived organoids and orthotopic xenografts of primary and recurrent gliomas represent relevant patient avatars for precision oncology 

      Golebiewska, Anna; Hau, Ann-Christin; Oudin, Anaïs; Stieber, Daniel; Yabo, Yahaya A.; Baus, Virginie; Barthelemy, Vanessa; Klein, Eliane; Bougnaud, Sébastien; Keunen, Olivier; Wantz, May; Michelucci, Alessandro; Neirinckx, Virginie; Muller, Arnaud; Kaoma, Tony; Nazarov, Petr V.; Azuaje, Francisco; De Falco, Alfonso; Flies, Ben; Richart, Lorraine; Poovathingal, Suresh K; Arns, Thais; Grzyb, Kamil; Mock, Andreas; Herold-Mende, Christel; Steino, Anne; Brown, Dennis; May, Patrick; Miletic, Hrvoje; Malta, Tathiane M.; Noushmehr, Houtan; Kwon, Yong-Jun; Jahn, Winnie; Klink, Barbara; Tanner, Georgette; Stead, Lucy F.; Mittelbronn, Michel; Skupin, Alexander; Hertel, Frank; Bjerkvig, Rolf; Niclou, Simone Pierrette (Journal article; Peer reviewed, 2020)
      Patient-based cancer models are essential tools for studying tumor biology and for the assessment of drug responses in a translational context. We report the establishment a large cohort of unique organoids and patient-derived ...

    • Targeting APLN/APLNR improves antiangiogenic efficiency and blunts proinvasive side effects of VEGFA/VEGFR2 blockade in glioblastoma 

      Mastrella, Giorgia; Hou, Mengzhuo; Li, Min; Stöcklein, Veit M.; Zdouc, Nina; Volmar, Marie N.M.; Miletic, Hrvoje; Reinhard, Sören; Herold-Mende, Christel C.; Kleber, Susanne; Eisenhut, Katharina; Gargiulo, Gaetano; Synowitz, Michael; Vescovi, Angelo L.; Harter, Patrick N.; Penninger, Josef M.; Wagner, Ernst; Mittelbronn, Michel; Bjerkvig, Rolf; Hambardzumyan, Dolores; Schüller, Ulrich; Tonn, Jörg Christian; Radke, Josefine; Glass, Rainer; Kälin, Roland E. (Peer reviewed; Journal article, 2019)
      Antiangiogenic therapy of glioblastoma (GBM) with bevacizumab, a VEGFA-blocking antibody, may accelerate tumor cell invasion and induce alternative angiogenic pathways. Here we investigate the roles of the proangiogenic ...